Zebrafish as model organisms for studying drug-induced liver injury

British Journal of Clinical Pharmacology

Volumn 78, Issue 6, 2014, Pages 1217-1227

  Vliegenthart, A D Bastiaan ^a   Tucker, Carl S ^b   Del Pozo, Jorge ^c   Dear, James W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Acetaminophen; Drug induced liver injury; Hepatotoxicity; Liver toxicity; Paracetamol; Zebrafish

Indexed keywords

BIOLOGICAL MARKER; DRUG; ENZYME; CYTOCHROME P450;

ANIMAL USE; ARTICLE; CONJUGATION; DEMETHYLATION; DRUG METABOLISM; ENZYME BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYDROXYLATION; IMMUNE SYSTEM; IN VIVO STUDY; INFLAMMATION; LIVER STRUCTURE; NONHUMAN; OXIDATION; PHENOTYPE; PHYSIOLOGICAL PROCESS; RODENT; TOXIC HEPATITIS; ZEBRA FISH; ANATOMY AND HISTOLOGY; ANIMAL; BLOOD; DISEASE MODEL; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; LIVER; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; BIOMARKERS; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; MICE; PHENOTYPE; ZEBRAFISH;

EID: 84919343903     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12408     Document Type: Article

References (85)

1. Bronstein AC, Spyker DA, Cantilena LR, Jr., Green J, Rumack BH, Heard SE. 2006 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila) 2007; 45: 815-917.
2. Hawton K, Bergen H, Simkin S, Dodd S, Pocock P, Bernal W, Gunnell D, Kapur N. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ (clinical research edition) 2013; 346: f403.
3. Lauterburg BH, Corcoran GB, Mitchell JR. Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest 1983; 71: 980-91.
4. Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and duration: past, present and future. Clin Toxicol (Phila) 2012; 50: 91-8.
5. Temple RJ. Hepatotoxicity through the years: impact on the FDA. 2001. Available at http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm122149.pdf (last accessed March 2014).
6. Farrell GC, Liddle C. Drugs and the liver updated, 2002. Semin Liver Dis 2002; 22: 109-13.
7. McDonnell ME, Braverman LE. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 2191-3; author reply 91-3.
8. Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into view. Nat Rev Genet 2007; 8: 353-67.
9. McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov Today 2008; 13: 394-401.
10. Barros TP, Alderton WK, Reynolds HM, Roach AG, Berghmans S. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol 2008; 154: 1400-13.
11. Lerche-Langrand C, Toutain HJ. Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 2000; 153: 221-53.
12. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001; 13: 343-68.
13. Schoonen WG, Westerink WM, de Roos JA, Debiton E. Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol in Vitro 2005; 19: 505-16.
14. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, Guguen-Guillouzo C, Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006; 34: 75-83.
15. Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, Suter L. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 2003; 73: 386-402.
16. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P, Brain P, Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 2006; 80: 580-604.
17. Chen JN, Haffter P, Odenthal J, Vogelsang E, Brand M, van Eeden FJ, Furutani-Seiki M, Granato M, Hammerschmidt M, Heisenberg CP, Jiang YJ, Kane DA, Kelsh RN, Mullins MC, Nusslein-Volhard C. Mutations affecting the cardiovascular system and other internal organs in zebrafish. Development (Cambridge, England) 1996; 123: 293-302.
18. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE, Humphray S, McLaren K, Matthews L, McLaren S, Sealy I, Caccamo M, Churcher C, Scott C, Barrett JC, Koch R, Rauch GJ, White S, Chow W, Kilian B, Quintais LT, Guerra-Assuncao JA, Zhou Y, Gu Y, Yen J, Vogel JH, Eyre T, Redmond S, Banerjee R, Chi J, Fu B, Langley E, Maguire SF, Laird GK, Lloyd D, Kenyon E, Donaldson S, Sehra H, Almeida-King J, Loveland J, Trevanion S, Jones M, Quail M, Willey D, Hunt A, Burton J, Sims S, McLay K, Plumb B, Davis J, Clee C, Oliver K, Clark R, Riddle C, Elliot D, Threadgold G, Harden G, Ware D, Mortimore B, Kerry G, Heath P, Phillimore B, Tracey A, Corby N, Dunn M, Johnson C, Wood J, Clark S, Pelan S, Griffiths G, Smith M, Glithero R, Howden P, Barker N, Stevens C, Harley J, Holt K, Panagiotidis G, Lovell J, Beasley H, Henderson C, Gordon D, Auger K, Wright D, Collins J, Raisen C, Dyer L, Leung K, Robertson L, Ambridge K, Leongamornlert D, McGuire S, Gilderthorp R, Griffiths C, Manthravadi D, Nichol S, Barker G, Whitehead S, Kay M, Brown J, Murnane C, Gray E, Humphries M, Sycamore N, Barker D, Saunders D, Wallis J, Babbage A, Hammond S, Mashreghi-Mohammadi M, Barr L, Martin S, Wray P, Ellington A, Matthews N, Ellwood M, Woodmansey R, Clark G, Cooper J, Tromans A, Grafham D, Skuce C, Pandian R, Andrews R, Harrison E, Kimberley A, Garnett J, Fosker N, Hall R, Garner P, Kelly D, Bird C, Palmer S, Gehring I, Berger A, Dooley CM, Ersan-Urun Z, Eser C, Geiger H, Geisler M, Karotki L, Kirn A, Konantz J, Konantz M, Oberlander M, Rudolph-Geiger S, Teucke M, Osoegawa K, Zhu B, Rapp A, Widaa S, Langford C, Yang F, Carter NP, Harrow J, Ning Z, Herrero J, Searle SM, Enright A, Geisler R, Plasterk RH, Lee C, Westerfield M, de Jong PJ, Zon LI, Postlethwait JH, Nusslein-Volhard C, Hubbard TJ, Roest Crollius H, Rogers J, Stemple DL, Begum S, Lloyd C, Lanz C, Raddatz G, Schuster SC. The zebrafish reference genome sequence and its relationship to the human genome. Nature 2013; 496: 498-503.
19. Briggs JP. The zebrafish: a new model organism for integrative physiology. Am J Physiol Regul Integr Comp Physiol 2002; 282: R3-9.
20. Santoriello C, Zon LI. Hooked! Modeling human disease in zebrafish. J Clin Invest 2012; 122: 2337-43.
21. Seth A, Stemple DL, Barroso I. The emerging use of zebrafish to model metabolic disease. Dis Model Mech 2013; 6: 1080-8.
22. Menke AL, Spitsbergen JM, Wolterbeek AP, Woutersen RA. Normal anatomy and histology of the adult zebrafish. Toxicol Pathol 2011; 39: 759-75.
23. Tao T, Peng J. Liver development in zebrafish (Danio rerio). J Genet Genomics 2009; 36: 325-34.
24. Isogai S, Horiguchi M, Weinstein BM. The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev Biol 2001; 230: 278-301.
25. Zhao R, Duncan SA. Embryonic development of the liver. Hepatology (Baltimore, Md) 2005; 41: 956-67.
26. Lorent K, Yeo SY, Oda T, Chandrasekharappa S, Chitnis A, Matthews RP, Pack M. Inhibition of Jagged-mediated Notch signaling disrupts zebrafish biliary development and generates multi-organ defects compatible with an Alagille syndrome phenocopy. Development (Cambridge, England) 2004; 131: 5753-66.
27. Goldstone JV, McArthur AG, Kubota A, Zanette J, Parente T, Jonsson ME, Nelson DR, Stegeman JJ. Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish. BMC Genomics 2010; 11: 643.
28. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6: 947-60.
29. Williams RT. The metabolism of certain drugs and food chemicals in man. Ann N Y Acad Sci 1971; 179: 141-54.
30. Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 2011; 10: 292-306.
31. Adams SS, Bough RG, Cliffe EE, Lessel B, Mills RF. Absorption, distribution and toxicity of ibuprofen. Toxicol Appl Pharmacol 1969; 15: 310-30.
32. Smith HS, Voss B. Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever. Drugs 2012; 72: 327-37.
33. Kepp DR, Sidelmann UG, Tjornelund J, Hansen SH. Simultaneous quantitative determination of the major phase I and II metabolites of ibuprofen in biological fluids by high-performance liquid chromatography on dynamically modified silica. J Chromatogr B Biomed Sci Appl 1997; 696: 235-41.
34. Brown CM, Reisfeld B, Mayeno AN. Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab Rev 2008; 40: 1-100.
35. Jones HS, Trollope HT, Hutchinson TH, Panter GH, Chipman JK. Metabolism of ibuprofen in zebrafish larvae. Xenobiotica 2012; 42: 1069-75.
36. Dahlin DC, Miwa GT, Lu AY, Nelson SD. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci U S A 1984; 81: 1327-31.
37. Laine JE, Auriola S, Pasanen M, Juvonen RO. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 2009; 39: 11-21.
38. Jemnitz K, Veres Z, Monostory K, Kobori L, Vereczkey L. Interspecies differences in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes. Toxicol in Vitro 2008; 22: 961-7.
39. Chng HT, Ho HK, Yap CW, Lam SH, Chan EC. An investigation of the bioactivation potential and metabolism profile of Zebrafish versus human. J Biomol Screen 2012; 17: 974-86.
40. Alderton W, Berghmans S, Butler P, Chassaing H, Fleming A, Golder Z, Richards F, Gardner I. Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae. Xenobiotica 2010; 40: 547-57.
41. Meuldermans W, Van Peer A, Hendrickx J, Lauwers W, Swysen E, Bockx M, Woestenborghs R, Heykants J. Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 1988; 16: 403-9.
42. Eichelbaum M, Ende M, Remberg G, Schomerus M, Dengler HJ. The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos 1979; 7: 145-8.
43. Mani S, Dou W, Redinbo MR. PXR antagonists and implication in drug metabolism. Drug Metab Rev 2013; 45: 60-72.
44. Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, Klaassen CD, Gonzalez FJ, Ma X. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med 2013; 19: 418-20.
45. Bresolin T, Rebelo M, Celso Dias Bainy A. Expression of PXR, CYP3A and MDR1 genes in liver of zebrafish. Comp Biochem Physiol C Toxicol Pharmacol 2005; 140: 403-7.
46. Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, Moore JT. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 2002; 16: 977-86.
47. Tseng HP, Hseu TH, Buhler DR, Wang WD, Hu CH. Constitutive and xenobiotics-induced expression of a novel CYP3A gene from zebrafish larva. Toxicol Appl Pharmacol 2005; 205: 247-58.
48. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005; 28: 249-68.
49. Rowlands JC, Gustafsson JA. Aryl hydrocarbon receptor-mediated signal transduction. Crit Rev Toxicol 1997; 27: 109-34.
50. Poellinger L, Gottlicher M, Gustafsson JA. The dioxin and peroxisome proliferator-activated receptors: nuclear receptors in search of endogenous ligands. Trends Pharmacol Sci 1992; 13: 241-5.
51. Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology (Baltimore, Md) 2013; 57: 1654-62.
52. Jaeschke H, Williams CD, Ramachandran A, Bajt ML. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 2012; 32: 8-20.
53. Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev 2012; 44: 107-15.
54. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6: 904-16.
55. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513-39.
56. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP. HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-9.
57. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, Aithal GP. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53: 1049-53.
58. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004; 101: 4180-5.
59. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
60. Berman J, Hsu K, Look AT. Zebrafish as a model organism for blood diseases. Br J Haematol 2003; 123: 568-76.
61. Bajoghli B. Evolution and function of chemokine receptors in the immune system of lower vertebrates. Eur J Immunol 2013; 43: 1686-92.
62. Jones M, Ball JS, Dodd A, Hill AJ. Comparison between zebrafish and Hep G2 assays for the predictive identification of hepatotoxins. Toxicology 2009; 262: 13-4.
63. Hill A, Mesens N, Steemans M, Xu JJ, Aleo MD. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. Drug Metab Rev 2012; 44: 127-40.
64. He JH, Guo SY, Zhu F, Zhu JJ, Chen YX, Huang CJ, Gao JM, Dong QX, Xuan YX, Li CQ. A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity. J Pharmacol Toxicol Methods 2013; 67: 25-32.
65. Zhang X, Li C, Gong Z. Development of a convenient in vivo hepatotoxin assay using a transgenic zebrafish line with liver-specific DsRed Expression. PloS ONE 2014; 9: e91874.
66. North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, Goessling W. PGE2-regulated wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci U S A 2010; 107: 17315-20.
67. Braunbeck T, Gorge G, Storch V, Nagel R. Hepatic steatosis in zebra fish (Brachydanio rerio) induced by long-term exposure to gamma-hexachlorocyclohexane. Ecotoxicol Environ Saf 1990; 19: 355-74.
68. Amali AA, Rekha RD, Lin CJ, Wang WL, Gong HY, Her GM, Wu JL. Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis. J Biomed Sci 2006; 13: 225-32.
69. Passeri MJ, Cinaroglu A, Gao C, Sadler KC. Hepatic steatosis in response to acute alcohol exposure in zebrafish requires sterol regulatory element binding protein activation. Hepatology (Baltimore, Md) 2009; 49: 443-52.
70. Murtha JM, Qi W, Keller ET. Hematologic and serum biochemical values for zebrafish (Danio rerio). Comp Med 2003; 53: 37-41.
71. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology (Baltimore, Md) 2011; 54: 1767-76.
72. Vliegenthart AD, Starkey Lewis P, Tucker CS, Del Pozo J, Rider S, Antoine DJ, Dubost V, Westphal M, Moulin P, Bailey MA, Moggs JG, Goldring CE, Park BK, Dear JW. Retro-orbital blood acquisition facilitates circulating microRNA measurement in zebrafish with paracetamol hepatotoxicity. Zebrafish 2014; 11: 219-26.
73. Cox AG, Saunders DC, Kelsey PB, Jr., Conway AA, Tesmenitsky Y, Marchini JF, Brown KK, Stamler JS, Colagiovanni DB, Rosenthal GJ, Croce KJ, North TE, Goessling W. S-nitrosothiol signaling regulates liver development and improves outcome following toxic liver injury. Cell Reports 2014; 6: 56-69.
74. Burns CG, Milan DJ, Grande EJ, Rottbauer W, MacRae CA, Fishman MC. High-throughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat Chem Biol 2005; 1: 263-4.
75. Berghmans S, Butler P, Goldsmith P, Waldron G, Gardner I, Golder Z, Richards FM, Kimber G, Roach A, Alderton W, Fleming A. Zebrafish based assays for the assessment of cardiac, visual and gut function-potential safety screens for early drug discovery. J Pharmacol Toxicol Methods 2008; 58: 59-68.
76. Langheinrich U. Zebrafish: a new model on the pharmaceutical catwalk. Bioessays 2003; 25: 904-12.
77. Doshna C, Benbow J, Depasquale M, Okerberg C, Turnquist S, Stedman D, Chapin R, Sivaraman L, Waldron G, Navetta K, Brady J, Banker M, Casimiro-Garcia A, Hill A, Jones M, Ball J, Aleo M. Multi-phase analysis of uptake and toxicity in Zebrafish: relationship to compound physical-chemical properties. Toxicol Sci 2009; 108: 78.
78. Van den Bulck K, Hill A, Mesens N, Diekman H, De Schaepdrijver L, Lammens L. Zebrafish developmental toxicity assay: a fishy solution to reproductive toxicity screening, or just a red herring? Reprod Toxicol 2011; 32: 213-9.
79. Diekmann H, Hill A. ADMETox in zebrafish. Drug Discov Today Dis Models 2013; 10: e31-e35.
80. Babaei F, Ramalingam R, Tavendale A, Liang Y, Yan LS, Ajuh P, Cheng SH, Lam YW. Novel blood collection method allows plasma proteome analysis from single zebrafish. J Proteome Res 2013; 12: 1580-90.
81. Jagadeeswaran P, Sheehan JP, Craig FE, Troyer D. Identification and characterization of zebrafish thrombocytes. Br J Haematol 1999; 107: 731-8.
82. Eames SC, Philipson LH, Prince VE, Kinkel MD. Blood sugar measurement in zebrafish reveals dynamics of glucose homeostasis. Zebrafish 2010; 7: 205-13.
83. Pedroso GL, Hammes TO, Escobar TD, Fracasso LB, Forgiarini LF, da Silveira TR. Blood collection for biochemical analysis in adult zebrafish. J Vis Exp 2012; 63: e3865.
84. Zang L, Shimada Y, Nishimura Y, Tanaka T, Nishimura N. A novel, reliable method for repeated blood collection from aquarium fish. Zebrafish 2013; 10: 425-32.
85. Ando H, Yanagihara H, Sugimoto K, Hayashi Y, Tsuruoka S, Takamura T, Kaneko S, Fujimura A. Daily rhythms of P-glycoprotein expression in mice. Chronobiol Int 2005; 22: 655-65.